Last week, the most important deals weren’t about devices. They were about the machinery underneath them.
KKR took the industry’s largest pure-play contract manufacturer private. Teleflex handed its OEM business to two more private equity firms and watched it re-emerge with a new name. Solventum announced it’s shedding software to become a “true medtech company.” Add CMS locking every hospital in America into mandatory joint replacement bundles, and a pattern emerges: the layer between your product and your revenue — who builds it, who pays for it, who owns the plumbing — is being redrawn while everyone watches the product headlines. If your commercialization plan assumes the infrastructure of 2024, last week was your notice.
Put your brand in front of 35,000+ medical device and med tech leaders each week. Contact us to learn more about sponsorship opportunities.
8 things to watch this week:
1. 🏦 KKR inks $5.7B deal to take medtech manufacturer Integer private
KKR agreed to acquire Integer Holdings — one of the world’s largest medical device CDMOs, serving cardiovascular, neuromodulation, and cardiac rhythm management markets — in an all-cash deal at $127 per share, expected to close by year-end. When a critical supplier to nearly every major strategic goes private, its investment priorities, capacity decisions, and pricing move out of public view — worth a conversation with your supply chain team before someone else’s diligence becomes your disruption.
Fierce Biotech
2. 🔧 Teleflex closes $1.5B OEM sale; business rebrands as Ingenyx
Teleflex completed the divestiture of its OEM contract manufacturing business to Montagu and Kohlberg on Monday, with the newly independent company launching as Ingenyx under continuing CEO Greg Stotts. Teleflex nets roughly $1.25 billion after tax, earmarked for debt paydown and buybacks — and the second major contract manufacturer in the same news cycle now answers to private equity rather than public shareholders.
MPO Magazine
3. 🧭 Where does your commercialization actually stand? Two minutes to find out.
Device companies rarely fail on technology — they fail on sequencing. RŌG Health's free Commercial Readiness Check scores your readiness across six dimensions and shows where you're strongest and most exposed. If you want help closing a gap, it'll point you to the right starting place.
Sponsored by RŌG Health
4. 🏛️ Medicare finalizes 2.3% hospital pay raise — and the first nationwide mandatory joint replacement model
CMS’s final FY 2027 inpatient rule delivers a 2.3% pay bump hospitals call inadequate — and finalizes CJR-X, the first mandatory, nationwide bundled payment model, covering hip, knee, and ankle replacement episodes starting January 2028 with $725 million in projected five-year savings. For ortho device makers, every hospital customer just became financially accountable for 90 days of episode cost — expect implant pricing, site-of-care, and post-acute utilization conversations to sharpen well before the start date.
MedTech Dive
5. 🦵 Smith+Nephew slashes revenue outlook as orthopedics stumbles
Smith+Nephew cut full-year revenue guidance from roughly 6% to 4% after U.S. knee implant revenue fell 7.2% in Q2, with hips reversing after four quarters of above-market growth and wound bioactives down double digits on reimbursement resets. Read items #4 and #5 together: U.S. ortho demand is softening at the exact moment Medicare is preparing to make every hospital accountable for what those procedures cost.
MD+DI
6. 🩸 FDA panel to review GRAIL’s Galleri multi-cancer blood test in September
The FDA’s Molecular and Clinical Genetics Panel will convene September 23 to review GRAIL’s PMA for Galleri, the multi-cancer early detection test, backed by data from 25,490 PATHFINDER 2 participants and over 70,000 from the NHS-Galleri trial. This is the highest-stakes advisory committee of the year in diagnostics: the panel will effectively set the evidentiary bar for an entire MCED category — and it comes months after Galleri’s UK trial missed its primary endpoint.
CLP Magazine
7. ⚠️ BD recalls vascular access system needles after 4 patient deaths
BD is recalling specific lots of its intraosseous vascular access needle sets after out-of-tolerance manufacturing dimensions left clinicians unable to remove the stylet — with 75 complaints, 45 serious injuries, and four deaths reported, all during out-of-hospital cardiac arrest resuscitations. The affected lots shipped over a 20-month window, a reminder that dimensional tolerance drift is a commercial risk, not just a quality metric.
MassDevice
8. 🧩 Solventum plans software separation to become ‘true medtech company’
Solventum will sell or spin off its $1.4 billion health information systems business — about 16% of revenue — following last year’s $4.1 billion filtration divestiture to Thermo Fisher, leaving a company focused on medsurg and dental. CEO Bryan Hanson explicitly left “portfolio optimization” on the table, which is 2026’s polite phrase for: nothing in the portfolio is safe if it dilutes the multiple.
MedTech Dive
🧭 About The Pathway
The Pathway is a curated briefing for medical device leaders, focused on regulatory moves, product launches, partnerships, and market signals shaping the industry.
If this was useful, consider subscribing or sharing with a colleague who should be tracking these developments.
Some issues may include sponsored or partner content. Sponsorship does not influence editorial selection of third-party news items.